timothy sykes logo
BIO Stock Pops As Elliott Targets Turnaround And RBC Sees Upside Thumbnail
G Google News

BIO Stock Pops As Elliott Targets Turnaround And RBC Sees Upside

BRYCE TUOHEY•UPDATED MAY. 18, 2026, 5:04 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Bio-Rad Laboratories Inc. stocks have been trading up by 13.93 percent after upbeat earnings and guidance boosted investor confidence.

Candlestick Chart

Live Update At 17:03:57 EDT: On Monday, May 18, 2026 Bio-Rad Laboratories Inc. stock [NYSE: BIO] is trending up by 13.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIO has started to wake up on the chart. After sliding from the high-$280s in late April to the mid-$240s by 2026/05/15, Bio-Rad Laboratories bounced sharply, closing at $281.82 on 2026/05/18. That is a strong three-day rip from $247.53 to the low-$280s, putting BIO back above its recent congestion zone.

Fundamentally, Q1 was messy but not broken. Bio-Rad Laboratories posted $592.1M in revenue, up about 1.1% year over year and slightly ahead of Wall Street expectations. Adjusted EPS at $1.89 dropped from $2.54 a year earlier and missed consensus, showing margin pressure even as sales grind higher. Still, BIO generated $108.1M of operating cash flow and $78.1M of free cash flow, real cash that matters more than headlines.

On the balance sheet, Bio-Rad Laboratories carries modest leverage, with long-term debt of about $941.5M against total equity of roughly $6.85B and a current ratio around 5.6. Valuation is not dirt cheap, with a price-to-sales near 2.6 and price-to-book just under 1.0, but BIO sits near book value with solid liquidity. For traders, that mix — improving price action, decent cash generation, and activist pressure — sets the stage for sharper moves as new catalysts hit.

Why Traders Are Watching BIO Now

BIO has moved from sleepy to spicy in a hurry, and the catalyst list is stacking up. The biggest headline is Elliott Investment Management building a significant stake in Bio-Rad Laboratories and making it clear it wants action to repair an underperforming share price. Activists like Elliott do not show up to watch from the sidelines. They show up to push for changes in costs, capital allocation, or portfolio focus, and the market usually prices in a higher chance of big shifts.

Layer that on top of RBC Capital Markets stepping back in with an Outperform rating and a $320 price target. RBC argues that Bio-Rad Laboratories is facing product-specific sales headwinds that should peak in 2026, with sales growth recovering in 2027. More important for traders, RBC highlights a self-help story: new management is targeting structural margin improvement, with EBIT margins guided to 11% in 2026 and aiming for the mid-teens over time. That is a classic “margin expansion plus activist pressure” setup.

Meanwhile, the tape confirms the story. BIO sold off hard into the mid-$240s, then ripped back to the low-$280s as the Elliott news and bullish RBC coverage hit. Intraday, the 5‑minute chart shows steady higher lows through the session and a close near the high at $281.82 — classic accumulation behavior rather than random noise.

At the same time, Bio-Rad Laboratories still faces real issues. Q1 adjusted EPS fell, and margins are under pressure. But BIO is throwing off cash, buying back shares, and, according to industry research, sits in a life science instrumentation market projected to grow from $63.4B in 2025 to $92.5B by 2031 at 6.5% annually. If execution improves, the macro wind is at BIO’s back — which is exactly the kind of mismatch activists like Elliott try to exploit.

More Breaking News

Conclusion

For active traders, BIO is shifting from a slow, grindy chart to a catalyst-rich battleground. On one side, you have the weak recent earnings trend — adjusted EPS declining from $2.54 to $1.89 and margin pressure showing up in the P&L. On the other, you have Bio-Rad Laboratories generating strong operating and free cash flow, maintaining a healthy balance sheet, and trading close to book value while a respected activist builds a large stake.

Add in RBC’s Outperform rating and $320 target, and you have a sell-side narrative that Bio-Rad Laboratories is a self-help story: company-specific headwinds in 2026, then a cleaner runway into 2027 with EBIT margins stepping up from 11% toward the mid-teens if management executes. Upcoming appearances at major healthcare conferences and continued communication with the street give BIO more potential news catalysts that can move the tape.

For the Tim Sykes crowd, this is where discipline matters. As Tim likes to hammer home, “The market rewards prepared traders, not hopeful gamblers.” As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. BIO is not a lottery ticket; it is a liquid, catalyst-driven stock where Elliott’s agenda, margin restructuring, and sector growth can all fuel volatility.

The edge comes from planning your trades around these catalysts, respecting levels on the daily and intraday charts, and cutting losses fast if the thesis breaks. Bio-Rad Laboratories will keep providing headlines. Traders’ job with BIO is to react with a clear plan, not emotion.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading BIO

Millionaire's
POV on BIO

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”